A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate

Trial Profile

A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Nasal congestion; Nasal polyps
  • Focus Registrational; Therapeutic Use
  • Acronyms NAVIGATE II
  • Sponsors OptiNose
  • Most Recent Events

    • 21 Jun 2018 According to an OptiNose media release, data from this trial were presented in Journal of Allergy and Clinical Immunology.
    • 18 Jun 2018 Results published in the Journal of Allergy and Clinical Immunology.
    • 05 Mar 2018 Results assessing the effect of Exhalation Delivery System with Fluticasone on Health-Related Quality of Life (n=242), presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top